Myocardial infarction as an initial symptom of antiphospholipid syndrome, factor V Leiden, and hyperhomocysteinemia;Zawał serca jako przejaw pierwotnego zespołu antyfosfolipidowego. Współudział czynnika V Leiden i hiperhomocysteinemii

Polskie Archiwum Medycyny Wewnetrznej

Volumn 111, Issue 1, 2004, Pages 63-67

  Dropiński, Jerzy ^a   Wȩgrzyn, Wojciech ^a   Szczeklik, Wojciech ^a   Krzanowski, Marek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antiphospholipid syndrome; Factor V Leiden; Hyperhomocysteinemia; Myocardial infarction; Thrombophilia

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE;

ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC ANALYSIS; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; LABORATORY TEST; MALE; RISK FACTOR; SYMPTOM; VITAMIN SUPPLEMENTATION;

EID: 1342311289     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bick R.L., Ismail Y., Baker W.F.: Caogulation abnormalities in patients with precocious coronary artery thrombosis and patients failing coronary artery bypass grafting and percutaneous transcoronary angioplasty. Sem. Thromb. Hemost., 1993, 19, 412.
2. Falk E., Fernandez-Oritiz A.: Role of thrombosis in atherosclerosis and its complications. Am. J. Cardiol., 1995, 75, 5.
3. Bertina R.M., Koelman B.PC., Koster T. i wsp.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 1994, 369, 64.
4. McCully K.S.: Homocysteine and vascular disease. Nature Medicine, 1996, 2, 386.
5. Ames P.R.J., Pyke S., Iannaccone L., Brancaccio V.: Antiphospholipid antibodies, haemostatic variables and thrombosis - a survey of 144 patients. Thromb. Haemost., 1995, 73, 768.
6. Hamsten A., Bjorholm M., Norberg R., de Faire U.: Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurent cardiovascular events. Lancet, 1986, 1, 113.
7. Vaarala O., Manttari M., Manninen V. i wsp.: Anticardiolipin antibodies and risk of myocardial infarction in prospective cohort of middle-aged men. Circulation, 1995, 91, 23.
8. Shapiro S.S.: The lupus anticoagulant/antiphospholipid syndrome. Annu. Rev. Med., 1996, 47, 533.
9. Brenner B., Blumenfeld Z., Markiewicz W., Reisner S.: Cardiac involvement in patients with primary antiphospholipid syndrome. J. Am. Coll. Cardiol., 1991, 18, 931.
10. Hojnik M., George J., Ziporen L. i wsp.: Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation, 1996, 92, 1579.
11. Asherson R.A., Cervera R.: Antiphospholipid antibodies and the heart. Circulation, 1991, 84, 920.
12. Musial J., Swadźba J., Jankowski M. i wsp.: Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid antibodies. Thromb. Haemost., 1997, 78, 1173.
13. Simantov R., Lo S.K., Gharavi A. i wsp.: Antiphospholipid antibodies activate vascular endothelial cells. Lupus, 1996, 5, 440.
14. Oosting J.D., Derksen R.H.W.M., Blokzij L. i wsp.: Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity - studies in a thrombosis model. Thromb. Haemost., 1992, 68, 278.
15. de Groot P.G., Horbach D.A., Derksen R.H.W.M.: Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus, 1996, 5, 488.
16. Asherson R.A., Cervera R.: Anticardiolipin antibodies, chronic biologic false-positive tests for syphilis and antiphospholipid antibodies. [w:] Wallace D.J., Hahn B.H., (red.) Duboi's Systemic Lupus Erythematosus. Philadelphia, Pa: Lea&Febiger, 1993, 233.
17. Saikku P., Leinonen M., Tenkanen L. i wsp.: Chronic chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. Med., 1992, 116, 273.
18. Domagala T.B., Undas A., Sydor W.J., Szczeklik A.: Thrombin formation in platelet-rich plasma after oral methionine loading. Preliminary report. Thrombosis Research, 2002, 105, 503.
19. Jankowski M., Sanak M., Axenti i wsp.: Zjawisko dziedzicznej trombofilii w miażdżycy tȩtnic i zakrzepicy żylnej: czynnik V Leiden i wariant 20210A genu protrombiny. Diagn. Lab., 1999, 35, 67.
20. Voutilainen S., Lakka T.A., Hamelahti P., Lehtimaki T., Poulsen H.E., Salonen J.T.: Plasma total homocysteine concentration and risk of acute coronary events: the Kuopio Ischaemic Heart Disease Pisk Factor Study. J. Intern. Med., 2000, 248, 217.
21. Loscalzo J.: The oxidant stress of hyperhomocysteinemia. J. Clin. Invest., 1996, 98, 5.
22. Koster T., Rosendaal F.R., de Ronde H., Biret E., Vandenbroucke J.P., Berlina R.M.: Venous thrombosis due to poor anticoagulant response to activated protein C.: Leiden Thrombophilia Study. Lancet, 1993, 342, 1503.
23. Dahlback B.: Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood, 1995, 85, 607.
24. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., Miletich J.P.: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. New. Engl. J. Med., 1995, 332, 912.
25. Mandel H., Brenner B., Berant M. i wsp.: Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. New Engl. J. Med., 1996, 334, 763.